RT Journal Article SR Electronic T1 The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with 177LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN). JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP jnumed.122.264104 DO 10.2967/jnumed.122.264104 A1 Sarennya Pathmanandavel A1 Megan Crumbaker A1 Andrew Nguyen A1 Andrew On Wah Yam A1 Peter Wilson A1 Remy Niman A1 Maria Ayers A1 Shikha Sharma A1 Peter Eu A1 Andrew J Martin A1 Martin R Stockler A1 Anthony M Joshua A1 Louise Emmett YR 2022 UL http://jnm.snmjournals.org/content/early/2022/06/23/jnumed.122.264104.abstract AB BACKGROUND: 177Lutetium PSMA-617 (177LuPSMA-617) therapy has shown high prostate specific antigen (PSA) response rates in men with metastatic castration-resistant prostate cancer (mCRPC). However early treatment resistance is common. This LUPIN sub-study aimed to determine the prognostic value of post-treatment quantitative PET for PSA progression free (PSA-PFS) and overall survival (OS) with 177LuPSMA-617 therapy. METHODS: 56 men with progressive mCRPC were enrolled in LuPIN trial and received up to 6 doses of 177LuPSMA-617 and a radiation sensitizer (NOX66). 68Ga-PSMA-11 and 18F-FDG PET/CT, diagnostic CT and bone scan were performed at study entry and exit. Quantitative analysis tracked change (Δ) in total tumour volume (TTV) and standardised uptake value (SUV). Univariable and multivariable analyses were conducted to examine the association of ΔTTV (continuous and > 30%), SUVmax, PSA and radiographic progression with PSA-PFS and OS. RESULTS: All men (37/56) who underwent both screening and post treatment molecular imaging were analyzed. 70% (26/37) had a PSA response >50%, median PSA-PFS was 8.6 months and median OS 22 months. Clinical progression had occurred at trial exit in 54% (20/37). 95% (35/37) demonstrated reduced PSMA SUVmax and 68% (25/37) reduced PSMA-TTV in response to treatment. An increase in PSMA-TTV ≥30% was associated with worse OS (median OS 10.2 vs 23.6 months, p 0.002). Change in PSMA-SUVmax was not associated with PSA-PFS or OS. FDG-SUVmax was reduced in 51% (18/35) and FDG -TTV in 67% (22/35). Increased FDG-SUVmax was associated with worse OS (median OS 20.7 vs. 25.7 months, p<0.01). Increased FDG-TTV > 30% was associated with short PSA-PFS (median PFS 3.5 vs 8.6 months, p<0.001) but not OS. Both PSA and radiographic progression were associated with shorter OS (median 14.5 vs 25.7 months, p<0.001, and 12.2 vs 23.6 months, p 0.002). On multivariable analysis, only increased PSMA-TTV and PSA progression remained independently prognostic of OS (HR 5.1 (95%CI 1.5-17.1), p 0.008 and HR 3.5 (95%CI 1.1-10.9), p 0.03 respectively). CONCLUSION: Change in quantitative PSMA-TTV has strong potential as a prognostic biomarker with 177LuPSMA-617 therapy, independent of FDG-PET parameters, PSA or radiographic progression. Further research into the value of post-treatment PET as imaging biomarker is warranted.